Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region

Clinical trial NCT04916509 · COMPLETED

Trial details

NCT number: NCT04916509
Sponsor: Pfizer
Status: COMPLETED
Study type: OBSERVATIONAL

Breast Neoplasms

Start date: 2021-09-13
Primary completion: 2022-12-27
Enrollment: 258

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.